The future of the medical industry will be shaped by a range of disruptive themes, with genomics being one of the themes that will have a significant impact on medical companies.
Genomics refers to the study of an entire set of DNA within an organism. This includes researching their molecular components, structures and functions of genes, and developing technologies that aim to map and edit sequences of DNA. What started as a global scientific endeavour to map the human genome in the 1990s, had also created an entirely new business market, whereby companies use genomic technologies to provide personal, direct-to-consumer genomic testing services. This enabled consumers to gain unprecedented insights into their health, well-being, and even family ancestry, all from a genomic perspective.
Players in the genomics market range from small private companies that specialise in specific value chains, to large corporations that dominate multiple industries. Three stages of the genomics value chain can be considered: technology manufacturers that enable the ability to analyse enormous amounts of genetic data, service providers of direct-to-consumer genetic testing, and service providers of third-party data-reanalysis.
However, not all companies are equal when it comes to their capabilities and investments in the key themes that matter most to their industry. Understanding how companies are positioned and ranked in the most important themes can be a key leading indicator of their future earnings potential and relative competitive position.
According to GlobalData’s thematic research report, Genomics in Medical Devices, leading adopters include: Illumina, InVitae, 23&Me, Ancestry.com and Veritas Genetics.
Insight from a top ranked company
Illumina provides genomic sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company’s portfolio encompasses sequencing tools and systems; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; and instrument services, training, and consulting. Illumina caters its services to pharmaceutical companies, genomic research centres, academic institutions, biotechnology companies, and clinical research organisations. The company sells its products through direct sales and distributors in the Americas, Asia-Pacific, Europe, the Middle East, and Africa. Illumina is headquartered in San Diego, California, US.
Illumina is the main original equipment manufacturer in the direct-to-consumer genetic testing market. The company provides the vast majority of SNP-BeadArray chips to key market leaders such as 23andMe, MyHeritage, and Ancestry.com. Additionally, it is a major player in the next-generation sequencing reagents market.
To further understand the key themes and technologies disrupting the industry, access GlobalData’s latest thematic research report on Genomics in Medical Devices.
- Zimmer Biomet
- Boston Scientific
- Becton Dickinson
- Nihon Kohden
- Intuitive Surgical
- Smith & Nephew
- Edwards Lifesciences